Virological features associated with the development of broadly neutralizing antibodies to HIV-1
about
Harnessing the protective potential of HIV-1 neutralizing antibodiesAntibody responses to envelope glycoproteins in HIV-1 infectionHIV broadly neutralizing antibody targetsHumanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Antibody 10-1074 suppresses viremia in HIV-1-infected individualsExploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo.HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortSequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization BreadthEffects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.A pathway to HIV-1 neutralization breadth.The Immune Fulcrum: Regulatory T Cells Tip the Balance Between Pro- and Anti-inflammatory Outcomes upon InfectionNeutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and DenmarkHIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens.An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy.HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious MononucleosisApproaches to the induction of HIV broadly neutralizing antibodies.B-cell responses to HIV infection.Identification and specificity of broadly neutralizing antibodies against HIVMammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins.Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.Determinants of HIV-1 broadly neutralizing antibody induction.Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.Conserved HIV Epitopes for an Effective HIV Vaccine.Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known EpitopesSex Differences in HIV Infection: Mystique Versus MachismoThe role of follicular helper CD4 T cells in the development of HIV-1 specific broadly neutralizing antibody responsesDevelopment of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
P2860
Q26766153-2A822AB5-9F01-4BB8-BB33-CB0E30DF38C4Q26991572-592BA2D7-CF72-4619-BB22-B5EE02E27D92Q27026662-A429263D-CE14-4F33-A5B5-46CE1202681EQ30234773-A459166A-72BA-497D-B4F4-65296F4A4C92Q33594304-A3FE59C1-6953-4263-A2FD-38057EA75838Q33786443-743E008C-A2EE-4B39-B8B3-102BDF3E979DQ33855697-8F64A683-4834-4190-8183-C9D18D592F9AQ34527469-908E1A3D-BE92-4867-A685-8CEFFAE97462Q35894094-34D33D66-1D8A-4F75-97EF-CA973A4F1BBEQ36132706-DDA2FB55-2D10-4657-A865-26528861C2EBQ36194234-3276874F-1BA2-4DF2-9276-2A1C115971BDQ36303368-18B82C13-2B98-41C9-9C95-8DF45B17F646Q36625139-CC484888-495D-40BC-B6D1-869E28FA9E4BQ36625426-B934A040-9037-4608-8446-98984FD2E661Q36837324-93CE2201-026D-456D-A5B8-56F29521ED8DQ37073506-C7A2974C-1CD5-47ED-9B64-AD333DBB7F96Q37417794-A0495F3F-A8B8-40EC-A1BD-5DB0331BA322Q37728775-151BE1F3-3580-41E3-81BE-F11252142F1FQ37741310-939502DB-4C5C-4291-8B1E-9347697C25A8Q38665463-87ECEFC0-87B6-49A4-8995-0175749D5B5BQ38735147-1462349A-8022-450C-8046-269CDC0D2F80Q38936867-B26EBAD4-8EEC-4664-B40F-BB66B2F87D87Q39108710-11A6ECAF-06DE-4A12-9A28-F179898D67D7Q39108796-8FFBF3BA-FBDD-492C-8C59-8E684993C3EBQ40080000-4A1768C6-3263-42EF-9E0E-6410BE93582FQ40103798-D2FE4684-C79D-4FC8-976B-F62943AAAB83Q40220988-8E3FE965-7420-4DB5-809B-DEDB9D3480F0Q40476608-B4076AB8-1A6E-4040-AD67-AFA6EF879712Q40568483-A6AEADE8-0BDB-4216-ADDE-8AFE7508164EQ40679052-8B5ED103-CB40-4D0E-B49C-E6F587C75340Q47093684-48E9B9C4-21C4-4C82-858A-C0896C409BE2Q47548910-24B7D2F3-D907-4F6A-A06F-A854E3DCF024Q52598776-73DC5833-5D5D-4654-8230-D464ED2A851FQ56913214-C0319BA0-762A-476F-A33D-BA59C5A9DDA0Q56996082-391E6C5B-7C32-4F44-BF5D-C772544D2AB7Q57170667-66710695-1120-4DA2-A520-3C4B2742BAD1Q58763247-F174D76E-C497-4FF2-8D21-F697B5025B1C
P2860
Virological features associated with the development of broadly neutralizing antibodies to HIV-1
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Virological features associate ...... utralizing antibodies to HIV-1
@ast
Virological features associate ...... utralizing antibodies to HIV-1
@en
Virological features associate ...... utralizing antibodies to HIV-1
@nl
type
label
Virological features associate ...... utralizing antibodies to HIV-1
@ast
Virological features associate ...... utralizing antibodies to HIV-1
@en
Virological features associate ...... utralizing antibodies to HIV-1
@nl
prefLabel
Virological features associate ...... utralizing antibodies to HIV-1
@ast
Virological features associate ...... utralizing antibodies to HIV-1
@en
Virological features associate ...... utralizing antibodies to HIV-1
@nl
P2860
P3181
P1476
Virological features associate ...... utralizing antibodies to HIV-1
@en
P2093
Penny L. Moore
P2860
P304
P3181
P356
10.1016/J.TIM.2014.12.007
P407
P577
2015-04-01T00:00:00Z